A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus

Trial Profile

A Randomized, Double-Blind, Active Comparator-Controlled, Crossover Study to Assess the Capacity of RAYOS® Compared to Immediate-Release Prednisone to Improve Fatigue and Control Morning Symptoms in Subjects With Systemic Lupus Erythematosus

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 Jun 2017

At a glance

  • Drugs Prednisone (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Acronyms RIFLE
  • Sponsors AMPEL BioSolutions
  • Most Recent Events

    • 28 Mar 2017 Status changed from planning to recruiting.
    • 11 Nov 2015 According to Horizon Pharma media release, this study is being conducted in collaboration with the Alliance for Lupus Research and will be carried out by the Lupus Clinical Investigators Network (LuCIN), across 25 sites in the USA.
    • 11 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top